Amin Afsahi, Hassan Mahmoudi, Azizalah Ebrahimi, Zahra Aeini and Davoud Esmaeili
Background and aims: Helicobacter pylori is one of the most common human infections, which colonizes more than half of the world’s population. This causes chronic stomach inflammation diseases without clinical syndromes, gastric and duodenal ulcer, and stomach cancer. Nowadays, the use of probiotics has received much consideration as one of the common therapeutic methods, which prevents bacterial colonization by creating a balance in the microbial gastrointestinal tract.
Methods: This experimental study was conducted on 30 rats in five groups from August 2016 to June 2017 in the Microbiology and Animal Laboratory of Shahrekord University. First, the rats were infected with H. pylori bacteria. PCR method was used to confirm the presence of bacteria in the stomach to ensure that the rats were inoculated with H. pylori. After inoculation, the infected rats were treated with probiotic product, and then gastric tissue of the infected group was evaluated by haematoxylin and eosin stain.
Results: The absence of Cag A and Ure C genes in fecal specimens of the group receiving probiotic products before and after H. pylori incubation showed a positive effect for this product on the prevention and treatment of H. pylori infection. Also, in stomach histology specimens, the effects of mild inflammation were observed in treated group with the probiotic product before and after H. pylori inoculation compared to the control group.
Conclusion: The results of this study showed that the addition of probiotic to a non-dairy product (broad bean extract) can be effective in preventing and treating H. pylori infection in the animal model.
Share this article
Cancer Science & Therapy received 5332 citations as per Google Scholar report
